{"id":201853,"date":"2024-12-18T12:23:51","date_gmt":"2024-12-18T18:23:51","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/12\/a-potential-new-treatment-option-for-chemotherapy-refractory-gastric-cancer"},"modified":"2024-12-18T12:23:51","modified_gmt":"2024-12-18T18:23:51","slug":"a-potential-new-treatment-option-for-chemotherapy-refractory-gastric-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/12\/a-potential-new-treatment-option-for-chemotherapy-refractory-gastric-cancer","title":{"rendered":"A Potential New Treatment Option for Chemotherapy-Refractory Gastric Cancer"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/a-potential-new-treatment-option-for-chemotherapy-refractory-gastric-cancer.jpg\"><\/a><\/p>\n<p>Regorafenib.<\/p>\n<hr>\n<p>For patients with metastatic esophagogastric adenocarcinoma, inhibition of the vascular endothelial growth factor (VEGF) pathway via the anti\u2013VEGFR-2 antibody ramucirumab increases response, progression-free survival (PFS) and overall survival (OS) when combined with second-line treatment with paclitaxel. The multitargeted tyrosine kinase inhibitor regorafenib targets VEGFR and other pathways and has effectiveness in chemotherapy-refractory colorectal cancer.<\/p>\n<p>Investigators now report results of the industry-sponsored, randomized, double-blind, placebo-controlled INTEGRATE IIa trial evaluating regorafenib (160 mg daily for 21 days of 28-day cycles) in patients with chemotherapy-refractory esophagogastric adenocarcinoma. Of the 251 patients enrolled, 63% were treated in Asia; 73% had gastric primaries; 42% had received a prior VEGF inhibitor; 59% had received two and 40% had received three or more lines of prior chemotherapy. For the analysis of OS, the primary endpoint, results were pooled with those from INTEGRATE I, a prior randomized, placebo-controlled, phase II trial in 147 patients.<\/p>\n<p>At a median follow-up of 48 months, OS was improved with regorafenib over placebo in the pooled cohort (hazard ratio, 0.70; P=0.001) and in the INTEGRATE IIa cohort (HR, 0.68; P=0.006). In the INTEGRATE IIa cohort, 1-year OS was improved with regorafenib (19% vs. 6%), whereas median OS was similar (4.0 and 4.5 months). PFS was improved with regorafenib (HR, 0.53; P0.0001). The disease control rate was higher with regorafenib than placebo (21.3% vs. 4.9%) and the antitumor response was limited (2.4% vs. 0%). Adverse events related to regorafenib, including palmar\u2013plantar erythrodysesthesia, mucositis, hypertension, and diarrhea, were manageable.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regorafenib. For patients with metastatic esophagogastric adenocarcinoma, inhibition of the vascular endothelial growth factor (VEGF) pathway via the anti\u2013VEGFR-2 antibody ramucirumab increases response, progression-free survival (PFS) and overall survival (OS) when combined with second-line treatment with paclitaxel. The multitargeted tyrosine kinase inhibitor regorafenib targets VEGFR and other pathways and has effectiveness in chemotherapy-refractory colorectal cancer. [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-201853","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/201853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=201853"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/201853\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=201853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=201853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=201853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}